Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Skyrizi came out with the largest Q2 impressions share of voice (SOV) spot for over-the-counter (OTC) pharma and Rx brands for the second year in a row, according to iSpot.tv data released this week.

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Buynetmeds.com has been sent a warning letter over the sale of opoioids and weight-loss drugs without a prescription.

GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when ...

The best stocks to invest in often are industry leaders in vast markets. These five stocks are likely to continue making ...